Core Viewpoint - Prestige Consumer Healthcare (PBH) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Prestige Consumer Healthcare suggest an improvement in the company's underlying business, likely leading to higher stock prices [5]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Prestige Consumer Healthcare to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns [10]. Earnings Estimate Revisions - Analysts have raised their earnings estimates for Prestige Consumer Healthcare, with the Zacks Consensus Estimate for the fiscal year ending March 2026 projected at $4.55 per share, showing a 0.7% increase over the past three months [8].